Mercia Technologies PLC has made a follow-on investment of £1.0million into Oxford Genetics, a synthetic biology company with significant expertise in DNA design. The investment follows the recent expansion of Oxford Genetics’ Board and its relocation to new, state-of-the-art facilities at Oxford Science Park.
Oxford Genetics first received seed investment via Mercia’s third party managed funds in 2013 as a founding investor before transitioning it to Mercia’s direct investment portfolio of ‘Emerging Stars’ in December 2015. Mercia has now invested £2.2million to date and holds 47.2% of the total issued share capital. This further capital support will enable Oxford Genetics to continue licensing its proprietary technology, SnapFast™, which makes DNA assembly significantly more efficient for research and production purposes within the rapidly expanding markets of Cell and Gene Therapy.
To view the full RNS announcement, please click here.